<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03726268</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00089977</org_study_id>
    <secondary_id>1R01DA042985-01</secondary_id>
    <nct_id>NCT03726268</nct_id>
  </id_info>
  <brief_title>Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement)</brief_title>
  <acronym>OSPREy</acronym>
  <official_title>Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this research is to improve perioperative pain treatment, decrease
      post-operative opioid consumption, diminish opioid related side effects, and reduce postop
      opioid prescribing (and hence opportunity for diversion, abuse, addiction, and fatal
      overdose).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol will test the innovative, paradigm-shifting hypothesis that anesthesia for
      outpatient surgery with long-duration opioids (methadone), compared with conventional
      short-duration opioids, achieves better analgesia, with similar or diminished side effects,
      may reduce development of chronic postsurgical pain, improves recovery, and importantly,
      decreases postoperative opioid consumption and could hence diminish take-home opioid
      prescribing and shrink the population reservoir of unused opioids available for diversion and
      misuse. Two cohorts will be studied, but analyzed separately. 1) Short-stay, anticipated
      next-day discharge surgery (compare short-duration vs long-duration opioid), 2) Same-day
      discharge surgery (compare short-duration vs long-duration opioid).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total 30 day post-discharge home opioid use (number of tablets)</measure>
    <time_frame>Approximately 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total intraoperative non-methadone opioid administration</measure>
    <time_frame>Approximately 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total PACU opioid administration</measure>
    <time_frame>Approximately 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital non-methadone opioid administration</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total 7d post-discharge home opioid use</measure>
    <time_frame>Up to 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Opioid Use</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>IV methadone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative and post-operative IV methadone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV fentanyl, sufentanil, morphine or hydromorphone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative and post-operative IV fentanyl, morphine or hydromorphone at anesthesia provider discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>Dose is 0.15-0.3 mg/kg IV methadone HCl given intraoperatively and in the immediate post-operative period. Intraoperative methadone doses are 15 mg in &quot;short-stay, anticipated next-day discharge&quot; patients (10 mg if ≤55kg), and 10 mg in &quot;same-day&quot; surgery patients.</description>
    <arm_group_label>IV methadone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).</description>
    <arm_group_label>IV fentanyl, sufentanil, morphine or hydromorphone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).</description>
    <arm_group_label>IV fentanyl, sufentanil, morphine or hydromorphone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).</description>
    <arm_group_label>IV fentanyl, sufentanil, morphine or hydromorphone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).</description>
    <arm_group_label>IV fentanyl, sufentanil, morphine or hydromorphone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age 18-65 years Undergoing general anesthesia and moderately painful ambulatory
             surgery with anticipated postop stay of &lt; 24 hours

          -  Signed, written, informed consent

        Exclusion Criteria

          -  History of liver or kidney disease.

          -  Females who are pregnant or nursing.

          -  Chronic opioid use (e.g. preoperative daily use of methadone, fentanyl transdermal
             patches, or ≥ 3 oxycodone pills)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Kharasch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evan Kharasch, MD</last_name>
    <phone>919-613-1154</phone>
    <email>katelynne.durrant@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicja Szydlowska, MBA</last_name>
    <phone>919-681-4377</phone>
    <email>alicja.szydlowska@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicja Szydlowska, MBA</last_name>
    </contact>
    <contact_backup>
      <email>alicja.szydlowska@duke.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

